Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells cancer
US10745489B2 · kind B2 · utility
0Cited by
5References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 21, 2018 |
| Grant date | Aug 18, 2020 |
| Priority date | — |
| Expiry date | May 21, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2440/10
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
An antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer, a pharmaceutical composition including the antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, the method including administering the antibody to the patient. A method for diagnosing a CSC, the use of the O-acetylated-GD2 ganglioside as a biomarker of CSC cancer, and a method for predicting the response of a subject affected with CSC cancer to a treatment with the antibody or the composition are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.